Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

BioEclipse Therapeutics
329 Oyster Point Blvd., 3rd Floor
S. San Francisco, CA 94080
Phone: 408-809-1030
https://www.bioeclipse.com/

BioEclipse Therapeutics is an emerging, clinical-stage biopharmaceutical company committed to delivering first-in-class, curative immuno-oncology therapeutics to patients with cancer. Our focus is on currently untreatable cancers where our unique multi-mechanistic combination approach could address needs of patients with cancers that most think are not treatable. BioEclipse Therapeutics is preparing to initiate Phase 1b/2a clinical trials with, CRX-100, a patented, first in class, intravenously delivered, targeted immunotherapy against solid tumors. CRX-100, is being developed to deliver potentially curative treatment to patients over a broad range of tumor types, including some rare pediatric cancers. BioEclipse Therapeutics is a resident company of Johnson & Johnson Innovation. JLABS, a premier life science incubator program.

Key Contact
Name
Pamela Contag
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
06/25/19 $7,700,000 Series A-1 DEFTA Partners
Plum Alley Investments
Revelis Capital Group
TEEC Angel Fund
Tsingyuan Ventures
undisclosed